Qiagen (NYSE:QGEN) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Qiagen (NYSE:QGEN) from a peer perform rating to an outperform rating in a research note issued to investors on Thursday, Marketbeat reports. Wolfe Research currently has $50.00 price objective on the stock.

QGEN has been the topic of a number of other research reports. JPMorgan Chase & Co. boosted their price target on shares of Qiagen from $52.00 to $54.00 and gave the stock an overweight rating in a research report on Tuesday, June 18th. Stifel Nicolaus dropped their price target on shares of Qiagen from $55.00 to $45.00 and set a hold rating on the stock in a research report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $51.05.

Qiagen Stock Down 0.0 %

NYSE:QGEN opened at $41.09 on Thursday. The firm’s 50 day simple moving average is $43.23 and its 200 day simple moving average is $43.57. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.45. Qiagen has a one year low of $34.74 and a one year high of $47.70. The company has a market cap of $9.38 billion, a PE ratio of 27.55, a P/E/G ratio of 3.18 and a beta of 0.42.

Qiagen (NYSE:QGEN) last posted its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. The business had revenue of $459.00 million for the quarter, compared to the consensus estimate of $453.91 million. During the same period last year, the company earned $0.53 EPS. The firm’s revenue was down 5.4% compared to the same quarter last year. On average, research analysts anticipate that Qiagen will post 2.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of QGEN. Vanguard Group Inc. increased its stake in Qiagen by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company’s stock valued at $382,856,000 after purchasing an additional 83,371 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in Qiagen by 0.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,481,873 shares of the company’s stock valued at $151,526,000 after purchasing an additional 26,078 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Qiagen by 8.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company’s stock valued at $1,045,211,000 after purchasing an additional 1,809,486 shares in the last quarter. Optiver Holding B.V. increased its stake in Qiagen by 1,211.4% during the 4th quarter. Optiver Holding B.V. now owns 47,212 shares of the company’s stock valued at $2,050,000 after purchasing an additional 43,612 shares in the last quarter. Finally, Sei Investments Co. increased its stake in Qiagen by 49.0% during the 4th quarter. Sei Investments Co. now owns 1,196,476 shares of the company’s stock valued at $51,963,000 after purchasing an additional 393,553 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.